01 1Gleevec
02 9Gleevec/Glivec
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,188
2019 Revenue in Millions : 1,263
Growth (%) : -6
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,024
2020 Revenue in Millions : 1,188
Growth (%) : -14
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 745
2021 Revenue in Millions : 1,024
Growth (%) : -27
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 561
2022 Revenue in Millions : 745
Growth (%) : -25
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 1.10%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 4,746
2014 Revenue in Millions : 4,658
Growth (%) : -2%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 3,323
2015 Revenue in Millions : 4,658
Growth (%) : -29
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 1,943
2016 Revenue in Millions : 3,323
Growth (%) : -42
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,561
2017 Revenue in Millions : 1,943
Growth (%) : -20%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 1,263
2018 Revenue in Millions : 1,561
Growth (%) : -19
LOOKING FOR A SUPPLIER?